Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy‐Induced Nausea and Vomiting

NEPA is the first fixed‐combination antiemetic composed of the neurokinin‐1 receptor antagonist netupitant (netupitant; 300 mg) and the 5‐hydroxytryptamine‐3 receptor antagonist palonosetron (palonosetron; 0.50 mg). This study evaluated the pharmacokinetic profiles of netupitant and palonosetron. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilmore, James, Bernareggi, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587462/
https://www.ncbi.nlm.nih.gov/pubmed/30412271
http://dx.doi.org/10.1002/jcph.1338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587462/
https://www.ncbi.nlm.nih.gov/pubmed/30412271
http://dx.doi.org/10.1002/jcph.1338

Ejemplares similares